Treat-to-Target Outcomes and Measures of Treatment Success in Three Phase 3 Trials of Tapinarof Cream 1% Once Daily for Mild to Severe Plaque Psoriasis

Main Article Content

April W Armstrong
Robert Bissonnette
Philip M Brown
Anna M Tallman
Kim A Papp


tapinarof, psoriasis, phase 3 trial, efficacy, cream




1. Armstrong AW, et al. J Am Acad Dermatol. 2017;76:290–298.

2. Pathirana D, et al. J Eur Acad Dermatol Venereol. 2009;23:5–70.

3. Mahil SK, et al. Br J Dermatol. 2020;182:1158–1166.

4. Strober BE, et al. Dermatol Ther. 2019;9:5–18.

5. Bagel J and Stein Gold L. J Drugs Dermatol. 2017;16:1209–1222.

6. Armstrong A, et al. J Eur Acad Dermatol Venereol. 2018;32:2200–2207.

7. Elmets CA, et al. J Am Acad Dermatol. 2021;84:432-470.

8. Dermavant Sciences. VTAMA (tapinarof) cream, 1%: US prescribing information. 2022. Accessed 22 July 2022.

9. Lebwohl M, et al. N Engl J Med. 2021;385:2219–2229.

10. Lebwohl M, et al. Presentation at: European Academy of Dermatology and Venereology; October 28 - November 1, 2020.

11. Strober B, et al. J Am Acad Dermatol. 2022.

12. National Psoriasis Foundation. Treat to Target. Accessed August 2022.

Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

1 2 3 4 5 > >>